Lariatin A
![]() |
- $183 - $345
- Product name: Lariatin A
- CAS: 732286-09-8
- MF: C94H143N27O25
- MW: 2051.34
- EINECS:
- MDL Number:
- Synonyms:Lariatin A;L-Proline, glycyl-L-seryl-L-glutaminyl-L-leucyl-L-valyl-L-tyrosyl-L-arginyl-L-α-glutamyl-L-tryptophyl-L-valylglycyl-L-histidyl-L-seryl-L-asparaginyl-L-valyl-L-isoleucyl-L-lysyl-, (8→1)-lactam;(8→1)-lactam glycyl-L-seryl-L-glutaminyl-L-leucyl-L-valyl-L-tyrosyl-L-arginyl-L-α-glutamyl-L-tryptophyl-L-valylglycyl-L-histidyl-L-seryl-L-asparaginyl-L-valyl-L-isoleucyl-L-lysyl-L-proline
4 prices
Selected condition:
Brand
- Adipogen Life Sciences
- Cayman Chemical
- Usbiological
Package
- 250ug
- 500μg
- 1mg
- ManufacturerAdipogen Life Sciences
- Product numberAG-CN2-0120-M001
- Product descriptionLariatinA ≥95%(HPLC)
- Packaging1mg
- Price$330
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number28165
- Product descriptionLariatin A
- Packaging500μg
- Price$183
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number28165
- Product descriptionLariatin A
- Packaging1mg
- Price$345
- Updated2024-03-01
- Buy
- ManufacturerUsbiological
- Product number044996
- Product descriptionLariatin A
- Packaging250ug
- Price$342
- Updated2021-12-16
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
Adipogen Life Sciences | AG-CN2-0120-M001 | LariatinA ≥95%(HPLC) | 1mg | $330 | 2021-12-16 | Buy |
Cayman Chemical | 28165 | Lariatin A | 500μg | $183 | 2024-03-01 | Buy |
Cayman Chemical | 28165 | Lariatin A | 1mg | $345 | 2024-03-01 | Buy |
Usbiological | 044996 | Lariatin A | 250ug | $342 | 2021-12-16 | Buy |
Properties
Density :1.48±0.1 g/cm3(Predicted)
storage temp. :Store at -20°C
solubility :Methanol: soluble; Water: soluble
form :A solid
storage temp. :Store at -20°C
solubility :Methanol: soluble; Water: soluble
form :A solid
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|